|
1
|
Sautès-Fridman C, Cherfils-Vicini J,
Damotte D, Fisson S, Fridman WH, Cremer I and Dieu-Nosjean MC:
Tumor microenvironment is multifaceted. Cancer Metastasis Rev.
30:13–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valastyan S and Weinberg RA: Tumor
metastasis: molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weis SM and Cheresh DA: Tumor
angiogenesis: molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: The role of the tumor-microenvironment in lung
cancer-metastasis and its relationship to potential therapeutic
targets. Cancer Treat Rev. 40:558–566. 2014. View Article : Google Scholar
|
|
6
|
Fokas E, McKenna WG and Muschel RJ: The
impact of tumor microenvironment on cancer treatment and its
modulation by direct and indirect antivascular strategies. Cancer
Metastasis Rev. 31:823–842. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Albini A and Sporn MB: The tumour
microenvironment as a target for chemoprevention. Nat Rev Cancer.
7:139–147. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang H and Declerck YA: Targeting the
tumor microenvironment: from understanding pathways to effective
clinical trials. Cancer Res. 73:4965–4977. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nguyen L, Fifis T and Christophi C:
Vascular disruptive agent OXi4503 and anti-angiogenic agent
Sunitinib combination treatment prolong survival of mice with CRC
liver metastasis. BMC Cancer. 16:5332016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyazaki Y, Shibuya M, Sugawara H,
Kawaguchi O and Hirsoe C: Salinomycin, a new polyether antibiotic.
J Antibiot (Tokyo). 27:814–821. 1974. View Article : Google Scholar
|
|
11
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dong TT, Zhou HM, Wang LL, Feng B, Lv B
and Zheng MH: Salinomycin selectively targets 'CD133+'
cell subpopulations and decreases malignant traits in colorectal
cancer lines. Ann Surg Oncol. 18:1797–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y: Effects of salinomycin on cancer
stem cell in human lung adenocarcinoma A549 cells. Med Chem.
7:106–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhi QM, Chen XH, Ji J, Zhang JN, Li JF,
Cai Q, Liu BY, Gu QL, Zhu ZG and Yu YY: Salinomycin can effectively
kill ALDH(high) stem-like cells on gastric cancer. Biomed
Pharmacother. 65:509–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen
G, Zhang TP, Kang T and Zhao YP: Combination of salinomycin and
gemcitabine eliminates pancreatic cancer cells. Cancer Lett.
313:137–144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ,
Zou CY, Xie XB, Zeng YX, Shen JN, Kang T, et al: Salinomycin
inhibits osteosarcoma by targeting its tumor stem cells. Cancer
Lett. 311:113–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li T, Liu X, Shen Q, Yang W, Huo Z, Liu Q,
Jiao H and Chen J: Salinomycin exerts anti-angiogenic and
anti-tumorigenic activities by inhibiting vascular endothelial
growth factor receptor 2-mediated angiogenesis. Oncotarget.
7:26580–26592. 2016.PubMed/NCBI
|
|
18
|
Wu D, Zhang Y, Huang J, Fan Z, Shi F and
Wang S: Salinomycin inhibits proliferation and induces apoptosis of
human nasopharyngeal carcinoma cell in vitro and suppresses tumor
growth in vivo. Biochem Biophys Res Commun. 443:712–717. 2014.
View Article : Google Scholar
|
|
19
|
Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL,
Wu SM, Cheng P, Zhang Y, Shen M, et al: Salinomycin inhibits
proliferation and induces apoptosis of human hepatocellular
carcinoma cells in vitro and in vivo. PLoS One. 7:e506382012.
View Article : Google Scholar
|
|
20
|
Kim SH, Choi YJ, Kim KY, Yu SN, Seo YK,
Chun SS, Noh KT, Suh JT and Ahn SC: Salinomycin simultaneously
induces apoptosis and autophagy through generation of reactive
oxygen species in osteosarcoma U2OS cells. Biochem Biophys Res
Commun. 473:607–613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He L, Wang F, Dai WQ, Wu D, Lin CL, Wu SM,
Cheng P, Zhang Y, Shen M, Wang CF, et al: Mechanism of action of
salinomycin on growth and migration in pancreatic cancer cell
lines. Pancreatology. 13:72–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KY, Kim SH, Yu SN, Park SK, Choi HD,
Yu HS, Ji JH, Seo YK and Ahn SC: Salinomycin enhances
doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR
human breast cancer cells via decreased efflux of doxorubicin. Mol
Med Rep. 12:1898–1904. 2015.PubMed/NCBI
|
|
23
|
Kim JH, Chae M, Kim WK, Kim YJ, Kang HS,
Kim HS and Yoon S: Salinomycin sensitizes cancer cells to the
effects of doxorubicin and etoposide treatment by increasing DNA
damage and reducing p21 protein. Br J Pharmacol. 162:773–784. 2011.
View Article : Google Scholar :
|
|
24
|
Managò A, Leanza L, Carraretto L, Sassi N,
Grancara S, Quintana-Cabrera R, Trimarco V, Toninello A, Scorrano
L, Trentin L, et al: Early effects of the antineoplastic agent
salinomycin on mitochondrial function. Cell Death Dis. 6:e19302015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ
and Carson DA: Salinomycin inhibits Wnt signaling and selectively
induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl
Acad Sci USA. 108:13253–13257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Y, Liang C, Xue F, Chen W, Zhi X,
Feng X, Bai X and Liang T: Salinomycin decreases doxorubicin
resistance in hepatocellular carcinoma cells by inhibiting the
β-catenin/TCF complex association via FOXO3a activation.
Oncotarget. 6:10350–10365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koo KH, Kim H, Bae YK, Kim K, Park BK, Lee
CH and Kim YN: Salinomycin induces cell death via inactivation of
Stat3 and downregulation of Skp2. Cell Death Dis. 4:e6932013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parajuli B, Lee HG, Kwon SH, Cha SD, Shin
SJ, Lee GH, Bae I and Cho CH: Salinomycin inhibits Akt/NF-κB and
induces apoptosis in cisplatin resistant ovarian cancer cells.
Cancer Epidemiol. 37:512–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huse JT and Holland EC: Targeting brain
cancer: advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ho AL, Koch MJ, Tanaka S, Eichler AF,
Batchelor TT, Tanboon J, Louis DN, Cahill DP, Chi AS and Curry WT
Jr: Impact of histopathological transformation and overall survival
in patients with progressive anaplastic glioma. J Clin Neurosci.
31:99–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dewan MC, White-Dzuro GA, Brinson PR,
Thompson RC and Chambless LB: Perioperative seizure in patients
with glioma is associated with longer hospitalization, higher
readmission, and decreased overall survival. J Neurosurg.
125:1033–1041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schaff LR and Lassman AB: Indications for
treatment: is observation or chemotherapy alone a reasonable
approach in the management of low-grade gliomas? Semin Radiat
Oncol. 25:203–209. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blondin NA and Becker KP: Anaplastic
gliomas: radiation, chemotherapy, or both? Hematol Oncol Clin North
Am. 26:811–823. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Viaccoz A, Lekoubou A and Ducray F:
Chemotherapy in low-grade gliomas. Curr Opin Oncol. 24:694–701.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Onishi M, Ichikawa T, Kurozumi K and Date
I: Angiogenesis and invasion in glioma. Brain Tumor Pathol.
28:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tate MC and Aghi MK: Biology of
angiogenesis and invasion in glioma. Neurotherapeutics. 6:447–457.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang X, Xu F, Li X, Ma C, Zhang Y and Xu
W: VEGF signal system: the application of antiangiogenesis. Curr
Med Chem. 21:894–910. 2014. View Article : Google Scholar
|
|
39
|
Zhang J and Hochwald SN: The role of FAK
in tumor metabolism and therapy. Pharmacol Ther. 142:154–163. 2014.
View Article : Google Scholar
|
|
40
|
Chen HC, Appeddu PA, Isoda H and Guan JL:
Phosphorylation of tyrosine 397 in focal adhesion kinase is
required for binding phosphatidylinositol 3-kinase. J Biol Chem.
271:26329–26334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Smith HW and Marshall CJ: Regulation of
cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010.
View Article : Google Scholar
|
|
42
|
Qin LS, Jia PF, Zhang ZQ and Zhang SM:
ROS-53-cyclophilin-D signaling mediates salinomycin-induced glioma
cell necrosis. J Exp Clin Cancer Res. 34:572015. View Article : Google Scholar
|
|
43
|
Zhang C, Tian Y, Song F, Fu C, Han B and
Wang Y: Salinomycin inhibits the growth of colorectal carcinoma by
targeting tumor stem cells. Oncol Rep. 34:2469–2476.
2015.PubMed/NCBI
|
